PLoS ONE (Jan 2015)

RAP1 GTPase overexpression is associated with cervical intraepithelial neoplasia.

  • Marcelo Antonio Pascoal-Xavier,
  • Anna Carolina Cançado Figueiredo,
  • Luciana Inácia Gomes,
  • Vanessa Peruhype-Magalhães,
  • Carlos Eduardo Calzavara-Silva,
  • Marcelo Azevedo Costa,
  • Ilka Afonso Reis,
  • Claudio Antônio Bonjardim,
  • Erna Geessien Kroon,
  • Jaquelline G de Oliveira,
  • Paulo César Peregrino Ferreira

DOI
https://doi.org/10.1371/journal.pone.0123531
Journal volume & issue
Vol. 10, no. 4
p. e0123531

Abstract

Read online

RAP1 (RAS proximate 1), a small GTP-binding protein of the RAS superfamily, is a putative oncogene that is highly expressed in several malignant cell lines and types of cancers, including some types of squamous cell carcinoma. However, the participation of RAP1 in cervical carcinogenesis is unknown. We conducted a cross-sectional study of paraffin-embedded cervical biopsies to determine the association of RAP1 with cervical intraepithelial neoplasia (CIN). Standard and quantitative immunohistochemistry assessment of RAP1 expression in fixed tissue was performed on 183 paraffin-embedded cervical biopsies that were classified as normal or non-dysplastic mucosa (NDM) (n = 33); CIN grade 1 (n = 84) and CIN grade 2/3 (n = 66). A gradual increase in RAP1 expression in NDM < CIN 1 < CIN 2/3 (p<0.001) specimens was observed and was in agreement with the histopathologic diagnosis. A progressive increase in the RAP1 expression levels increased the risk of CIN 1 [odds ratio (OR) = 3.50; 95% confidence interval (CI) 1.30-10.64] 3.5 fold and the risk of CIN 2/3 (OR = 19.86, 95% CI 6.40-70.79) nearly 20 fold when compared to NDM. In addition, stereotype ordinal regression analysis showed that this progressive increase in RAP1 expression more strongly impacted CIN 2/3 than CIN 1. Our findings suggest that RAP1 may be a useful biomarker for the diagnosis of CIN.